当前位置:肝健康 > 资讯信息 > 肝健康声明:医疗信息具有强领域专业性,就诊用药需谨慎。

About China Liver Health

来源:中联肝健康促进中心 日期:2019-12-07 13:24;作者:中联肝健康促进中心    

  Academician Zhuang Hui, honorary chairman
Academician Zhuang Hui, honorary chairman
Professor Wei Lai, chairman of the board
  Professor Wei Lai, chairman of the board
 
  Who We Are
 
  China Liver Health (CLH) is established in September, 2016 with the approval of Ministry of Civil Affairs of the People’s Republic of China. Under the charge of Ministry of Civil Affairs, it is a non-profit social institution engaged in scientific popularization, public aid and health promotion for liver health.
 
  CLH is initiated by Professor Zhuang Hui from Peking University Health Science Center, also an academician of Chinese Academy of Engineering, a famous expert in infectious disease and a main promoter for newborn hepatitis B vaccination in China. The establishment of CLH receives guidance and assistance from government departments including the Ministry of Civil Affairs and National Health and Family Planning Commission, and professional organizations like the World Health Organization (WHO), Chinese Foundation for Hepatitis Prevention and Control and Chinese Medical Association. Jia Jidong, Hou Jinlin, Wei Lai and other distinguished experts also provide ardent supports.
 
  Professor Wei Lai, the director of Hepatobiliary and Pancreatic Center, Beijing Tsinghua Changgung Hospital and former chairman of Chinese Society of Hepatology under Chinese Medical Association, is nominated as the first chairman of CLH jointly by organizers, investors, staff representatives and business units. Professor Zhuang Hui serves as the honorary chairman.
 
  Our Mission
 
  In compliance with the constitution, laws, regulations, national policies and social morality, CLH is engaged in liver health promotion for the whole society, especially targeting at young people, children, the elderly and vulnerable groups, so as to make contributions to the improvement of prevention and control for liver diseases.
 
  In recent decades, China has made great achievements in public health sector. However, various types of liver diseases are still a serious threat to the health of general public, including infectious diseases caused by viruses like hepatitis B and hepatitis C and also chronic diseases associated with unhealthy lifestyles like fatty liver and alcoholic liver disease. Liver diseases not only bring about huge social burden and impoverish a number of patients, but also make many patients suffer from psychological problems due to social discrimination against them.
 
  The prevention and control of liver diseases needs efforts from the social system. In addition to scientific immunization and standard treatment in the medical sector, it is necessary to develop health education and popularize knowledge of liver health for the pubic and provide public aid for the elderly, young, poor, sick and infected people.
 
  As the only social service institution in liver health nationwide, CLH aims to build a platform for the cooperation among relevant experts, volunteers and institutions to raise public’s awareness of liver health, promote prevention and standard diagnosis and treatment for liver diseases, reduce the burden of disease and eliminate social discrimination against patients with hepatitis.
 
  Our Services
 
  CLH specializes in academic exchanges, scientific popularization promotion, book editing, survey and research, international cooperation and advisory services in the field of liver health promotion, including:
 
  1) Cooperating with medical colleges, professional societies, foundations, research institutes, medical institutions and pharmaceutical enterprises to carry out liver health promotion activities in primary hospitals, communities and schools;
 
  2) Organizing and mobilizing volunteers to carry out medical training, immunoprophylaxis, disease diagnosis and treatment, patient education and relevant media publicity, based on the service needs of doctors, patients and medical institutions;
 
  3) Promoting scientific research in the prevention, diagnosis, treatment and rehabilitation of liver diseases and carrying out professional training and technical consultation under the guidance of liver specialists as well as undertaking national or international projects and researches in the field of liver health.

About China Liver Health》由肝健康整理提供,转载请注明!原创另行标注!请尊重版权!http://www.gjk.org.cn/xinwenzixun/14962.html

版权声明:秉承互联网开放、包容的精神,肝健康欢迎各方(自)媒体、机构转载、引用我们原创内容,但要严格注明来源肝健康;同时,我们倡导尊重与保护知识产权,如发现本站文章存在版权问题,烦请将版权疑问、授权证明、版权证明、联系方式等,发邮件至15021331217@139.com,我们将第一时间核实、处理。部分图片来源网络,版权归原作者所有,仅作分享之用,如果分享内容侵犯您的版权或者所标来源非第一原创,请私信小编,我们会及时审核并做删除处理。

分享到: 更多


肝病科普

  • JCH:乙型肝炎患者骨质疏松的

    骨质疏松是一种常见的以骨密度减低、骨微组织破坏导致骨脆性及骨折风险增加为主要特点的全身骨疾病......

  • 替诺福韦和恩替卡韦均可有效

    目前指南建议接受免疫抑制治疗的HBsAg 和(或)抗-HBc IgG阳性患者应用预防性抗HBV治疗,以防止HBV再激活。......

  • 大三阳转小三阳是好事吗

    大三阳和小三阳,只是反映人体内携带病毒的状况,并不能反映病情严重程度,要想了解病情轻重,需要全面检查肝功能、肝脏......

肝健康

爱肝 护肝
肝健康与肝友一起战胜肝炎

风雨同舟
消除乙肝歧视,关爱肝病人群

友情链接

关于我们|发展历史|联系我们|版权声明

本站内容均来自网络,如侵犯您的权利请联系我们处理。QQ邮箱:1032475243@qq.com
肝健康 版权所有 Copyright © 2018 中华人民共和国工业和信息化部ICP备案号:备案号:沪ICP备14035080号-4
肝健康网声明:本站上的信息仅供参考,不能代替您去医院进行治疗,您不能凭本网站上的信息诊断疾病或开处方,以免影响您的健康。如未到医院就医,并未遵照医生诊断和治疗建议,自行使用本网资料发生偏差,本站概不负责,亦不负任何法律责任。